| Literature DB >> 26178328 |
Luiz Carlos Hespanhol Junior1, Julian David Pillay2, Willem van Mechelen3, Evert Verhagen4.
Abstract
BACKGROUND: In order to implement running to promote physical activity, it is essential to quantify the extent to which running improves health.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26178328 PMCID: PMC4579257 DOI: 10.1007/s40279-015-0359-y
Source DB: PubMed Journal: Sports Med ISSN: 0112-1642 Impact factor: 11.136
Fig. 1Flow of the studies during the selection process. The databases searched were: PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), SPORTDiscus, Physiotherapy Evidence Database (PEDro), the Cochrane Library and Latin American and Caribbean Center on Health Sciences Information (LILACS). BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein, RCT randomised controlled trial, VO maximal oxygen uptake
Risk of bias assessment of included studies
| References | Year | Cochrane Collaboration tool [ | Intention-to-treat analysis | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Randomisation | Concealed allocation | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other bias | |||
| Moghadasi and Mohammadi Domieh [ | 2014 | ? | ? | − | − | + | ? | + | ? |
| Celik et al. [ | 2013 | + | + | − | Blood samples: + | + | ? | + | ? |
| Gregory et al. [ | 2013 | ? | ? | − | − | − | ? | + | ? |
| Asad et al. [ | 2012 | ? | ? | − | − | + | ? | + | ? |
| Hosseini et al. [ | 2012 | ? | ? | − | − | + | ? | + | ? |
| Lo et al. [ | 2011 | ? | ? | − | − | + | ? | + | ? |
| Andersen et al. [ | 2010 | ? | ? | − | Echocardiography: + | + | ? | + | ? |
| Hendrickson et al. [ | 2010 | ? | ? | − | − | ? | − | + | ? |
| Krustrup et al. [ | 2010 | − | − | − | Echocardiography: + | − | ? | + | ? |
| Nindl et al. [ | 2010 | ? | ? | − | − | + | − | + | ? |
| Ozdemir et al. [ | 2010 | ? | ? | − | − | + | ? | + | ? |
| Sedlock et al. [ | 2010 | ? | ? | − | − | + | ? | + | ? |
| Lee et al. [ | 2009 | ? | ? | − | − | + | ? | + | ? |
| Lester et al. [ | 2009 | + | ? | − | − | + | ? | + | ? |
| Brixius et al. [ | 2008 | ? | ? | − | − | + | ? | + | ? |
| Meyer et al. [ | 2007 | ? | ? | − | − | + | ? | + | ? |
| Ring-Dimitriou et al. [ | 2007 | ? | ? | − | Blood samples: + | − | ? | + | ? |
| Beneke and Hutler [ | 2005 | ? | ? | − | − | + | ? | + | ? |
| Hautala et al. [ | 2004 | ? | ? | − | − | + | ? | + | ? |
| Poehlman et al. [ | 2000 | ? | ? | − | − | − | ? | + | ? |
| Bourque et al. [ | 1997 | ? | ? | − | − | − | − | + | ? |
| Hubinger and Mackinnon [ | 1996 | ? | ? | − | − | − | ? | + | ? |
| Suter et al. [ | 1994 | ? | ? | − | − | + | ? | + | ? |
| Garber et al. [ | 1992 | ? | ? | − | − | − | ? | + | ? |
| Suter and Marti [ | 1992 | ? | ? | − | − | + | ? | + | ? |
| Williams et al. [ | 1992 | ? | ? | − | − | + | ? | + | ? |
| Oja et al. [ | 1991 | ? | ? | − | − | + | − | + | ? |
| Marti et al. [ | 1990 | ? | ? | − | − | + | ? | + | + |
| Suter et al. [ | 1990 | ? | ? | − | − | + | ? | + | ? |
| Williams et al. [ | 1990 | ? | + | − | − | + | ? | + | ? |
| Williams et al. [ | 1990 | ? | ? | − | − | + | − | + | ? |
| Moses et al. [ | 1989 | ? | ? | − | − | − | − | + | ? |
| Williams et al. [ | 1989 | ? | ? | − | − | + | ? | + | ? |
| Wood et al. [ | 1988 | ? | + | − | − | + | ? | + | ? |
| Juneau et al. [ | 1987 | ? | ? | − | − | + | − | + | ? |
| Allen et al. [ | 1986 | ? | ? | − | − | + | ? | + | ? |
| Gossard et al. [ | 1986 | ? | ? | − | − | + | ? | + | ? |
| Hagan et al. [ | 1986 | ? | ? | − | − | + | − | + | ? |
| Mueller et al. [ | 1986 | ? | ? | − | − | ? | ? | + | ? |
| Savage et al. [ | 1986 | ? | ? | − | − | + | ? | + | ? |
| Thomas et al. [ | 1985 | ? | ? | − | − | − | ? | + | ? |
| Iltis et al. [ | 1984 | ? | ? | − | − | + | ? | + | ? |
| Mathur and Toriola [ | 1984 | ? | ? | − | − | + | ? | + | ? |
| Thomas et al. [ | 1984 | − | ? | − | − | − | ? | + | ? |
| Toriola [ | 1984 | ? | ? | − | − | + | ? | + | ? |
| Williams et al. [ | 1983 | ? | ? | − | − | − | ? | + | ? |
| Wood et al. [ | 1983 | ? | + | − | − | + | ? | + | ? |
| Williams et al. [ | 1982 | ? | ? | − | − | + | ? | + | ? |
| Wilmore et al. [ | 1980 | + | ? | − | − | + | − | + | ? |
Source of bias: selection bias (randomisation and concealed allocation), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data: >20 %), reporting bias (selective reporting) and other source of bias
BC body composition, BP blood pressure, DXA dual energy X-ray absorptiometry, FG fasting glucose, RHR resting heart rate, VO maximal oxygen uptake, + low risk of bias (plausible bias unlikely to seriously alter the results), − high risk of bias (plausible bias that seriously weakens confidence in the results), ? unclear risk of bias (plausible bias that raises some doubt about the results)
Meta-analyses on the effects of running on biomedical indices of health
| Outcome measure | Subgroup analysis by length of training | Subgroup analysis by sex | |||
|---|---|---|---|---|---|
| 12 weeks | 26 weeks | 52 or 69 weeks | Males | Females | |
| Body composition | |||||
| Body mass (kg) | −0.9 (−2.6 to 0.8) | −0.9 (−3.6 to 1.9) | −3.3 (−4.1 to −2.5)* | −3.1 (−3.8 to −2.3)* | −0.6 (−2.5 to 1.4) |
| Heterogeneity |
|
|
|
|
|
| Lean body mass (kg) | −0.6 (−2.0 to 0.8) | −0.1 (−0.6 to 0.3) | −0.1 (−2.2 to 2.1) | −0.2 (−1.2 to 0.9) | −0.3 (−1.5 to 0.8) |
| Heterogeneity |
|
|
|
|
|
| Body fat (%) | −1.3 (−2.0 to −0.6)* | −1.9 (−2.8 to −1.0)* | −2.7 (−5.1 to −0.2)* | −1.8 (−2.3 to −1.3)* | 0.4 (−1.7 to 2.6) |
| Heterogeneity |
|
|
|
|
|
| BMI (kg m−2) | −0.6 (−2.2 to 1.0) | −0.2 (−0.6 to 0.2) | −0.2 (−1.4 to 1.0) | −0.3 (−0.7 to 0.2) | 0.0 (−1.1 to 1.1) |
| Heterogeneity |
|
|
|
|
|
| Cardiorespiratory | |||||
| Resting heart rate (min−1) | −3.4 (−5.6 to −1.2)* | −3.5 (−6.7 to −0.3)* | −6.7 (−10.3 to −3.0)* | −4.6 (−6.5 to −2.7)* | −2.6 (−5.7 to 0.5) |
| Heterogeneity |
|
|
|
|
|
| | 3.8 (3.1 to 4.6)* | 4.1 (3.0 to 5.1)* | 7.1 (5.0 to 9.1)* | 4.6 (3.9 to 5.3)* | 3.0 (1.7 to 4.3)* |
| Heterogeneity |
|
|
|
|
|
| Blood serum concentration | |||||
| Triglycerides (mg dl−1) | −12.9 (−24.6 to −1.2)* | −6.0 (−26.1 to 14.1) | −16.9 (−28.1 to −5.6)* | −13.8 (−21.8 to −5.8)* | −15.2 (−38.6 to 8.2) |
| Heterogeneity |
|
|
|
|
|
| Total cholesterol (mg dl−1) | −5.3 (−10.0 to −0.5)* | 11.7 (1.4 to 22.0)* | −2.2 (−7.8 to 3.3) | −2.5 (−6.0 to 1.1) | 0.4 (−14.2 to 15.0) |
| Heterogeneity |
|
|
|
|
|
| HDL cholesterol (mg dl−1) | −0.2 (−3.7 to 3.4) | 2.0 (−1.0 to 4.9) | 3.3 (1.2 to 5.4)* | 2.6 (1.0 to 4.2)* | 2.8 (−3.0 to 8.6) |
| Heterogeneity |
|
|
|
|
|
| LDL cholesterol (mg dl−1) | −0.7 (−11.7 to 10.4) | 9.8 (−2.3 to 21.9) | −2.6 (−7.6 to 2.4) | −0.4 (−4.9 to 4.2) | 0.3 (−13.6 to 14.2) |
| Heterogeneity |
|
|
|
|
|
All estimates came from the random-effects meta-analysis comparing the intervention groups (endurance running) with the control groups (physically inactive)
BMI body mass index, CI confidence interval, HDL high-density lipoprotein, LDL low-density lipoprotein, VO maximal oxygen uptake, WMD weighted mean difference
* Statistically significant estimate (95% CI around the WMD not including zero)
Dose-response analysis on the effects of running on biomedical indices of health
| Outcome measure | Length of training (weeks) | Frequency (sessions/week) | Duration (h/week) | Distance (km/week) | Intensity (%HRmax) | Speed (km/h) |
|---|---|---|---|---|---|---|
| Body composition | ||||||
| Body mass (kg) | −0.06 (−0.12 to −0.01)* | −0.19 (−1.63 to 1.24) | 0.55 (−0.90 to 2.00) | −0.20 (−0.62 to 0.23) | 0.25 (−0.02 to 0.52) | – |
| Lean body mass (kg) | 0.00 (−0.05 to 0.06) | −0.46 (−1.45 to 0.53) | −0.33 (−1.09 to 0.44) | – | – | – |
| Body fat (%) | −0.05 (−0.09 to 0.00) | 0.07 (−0.78 to 0.92) | 0.22 (−0.35 to 0.79) | – | 0.24 (−0.03 to 0.52) | – |
| BMI (kg m−2) | 0.00 (−0.06 to 0.07) | −0.04 (−0.79 to 0.71) | −0.21 (−1.11 to 0.68) | – | – | – |
| Cardiorespiratory | ||||||
| Resting heart rate (min−1) | −0.07 (−0.18 to 0.04) | 1.60 (−0.45 to 3.66) | 1.50 (−0.49 to 3.48) | – | – | – |
| | 0.07 (0.03 to 0.11)* | −0.10 (−0.88 to 0.68) | −0.71 (−1.32 to −0.11)* | – | −0.07 (−0.30 to 0.15) | – |
| Blood serum concentration | ||||||
| Triglycerides (mg dl−1) | −0.08 (−0.57 to 0.41) | −2.48 (−14.61 to 9.65) | −1.87 (−9.52 to 5.78) | −0.85 (−3.08 to 1.37) | – | 1.19 (−2.08 to 4.47) |
| Total cholesterol (mg dl−1) | 0.06 (−0.18 to 0.29) | 4.40 (−1.13 to 9.93) | 3.52 (−0.06 to 7.09) | 0.27 (−0.69 to 1.22) | – | −0.59 (−1.96 to 0.78) |
| HDL cholesterol (mg dl−1) | 0.07 (−0.03 to 0.18) | −2.10 (−6.29 to 2.09) | 1.71 (−2.12 to 5.53) | – | – | – |
| LDL cholesterol (mg dl−1) | −0.19 (−0.51 to 0.12) | 4.67 (−5.32 to 14.65) | – | – | – | – |
All estimates came from the random-effects meta-regression using the mean difference between the intervention groups (endurance running) and the control groups (physically inactive) as the dependent variable, and the running characteristics as numeric linear predictors. The average of the weekly running speed (km/h) was calculated dividing the weekly running distance (km/week) by the weekly duration (h/week)
β linear regression coefficient, %HR percentage of maximum heart rate, BMI body mass index, CI confidence interval, HDL high-density lipoprotein, LDL low-density lipoprotein, VO maximal oxygen uptake, “–” not applicable
* Statistically significant estimate (95 % CI around β not including zero)
| Endurance running was found to be beneficial for health in physically inactive adults with regards to body mass, body fat, resting heart rate, maximal oxygen uptake, triglycerides and high-density lipoprotein cholesterol. |
| The effects of running on biomedical indices of health are beneficially correlated to running exposure. |
| Clinicians and health authorities can use this information to advise individuals to run, and also to support policies towards investing in running programs. |